^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    COMPANY:
    Nonagen BioSci

    i
    Other names: Nonagen BioSci | Nonagen Bioscience Corporation | Nonagen Bioscience
    Related tests:
    Evidence

    News

    over1year
    DiaCarta Announces Successful Completion of Oncuria Validation Study with Nonagen Bioscience (DiaCarta Press Release)
    "DiaCarta, Ltd...announced the successful completion of the validation study of Oncuria® multiplex bladder cancer immunoassay as a laboratory developed test ('LDT'). DiaCarta also announced that it has begun receiving patient urine samples for testing in its CLIA certified lab in Pleasanton, California."
    Clinical data
    |
    Oncuria™
    almost2years
    Nonagen Bioscience announces CE Mark for Oncuria® bladder cancer diagnostic (Nonagen Bioscience Press Release)
    "Nonagen Bioscience...announced CE marking for its Oncuria® immunoassay for bladder cancer...Oncuria now bears the CE marking and is registered under the EU In Vitro Diagnostic Directive (IVDD), EU Directive 98/79/EC, which allows Nonagen to sell the diagnostic in the European market."
    European regulatory
    |
    Oncuria™
    almost2years
    Nonagen Bioscience and Bio-Techne announce exclusive supply agreement for Nonagen’s Oncuria® bladder cancer test (Nonagen Bioscience Press Release)
    "Nonagen Bioscience and Bio-Techne Corporation...announced an agreement for R&D Systems, a Bio-Techne brand, to exclusively manufacture Nonagen Bioscience’s Oncuria® bladder cancer diagnostic panel using xMAP Luminex® technology...Nonagen Bioscience and Bio-Techne are targeting the last quarter of calendar 2022 to make Oncuria available as an LDT."
    Licensing / partnership
    |
    Oncuria™
    2years
    Nonagen Bioscience looks to Peregrine Market Access to lead the commercialization of innovative bladder cancer diagnostic test (Pharmalive)
    "Peregrine Market Access...has been selected by Nonagen Bioscience to become its contract commercialization organization for Oncuria, a breakthrough bladder cancer diagnostic test that is being developed to aid in detection, therapy choice, and disease monitoring. Under a multiyear, multimillion dollar agreement, Peregrine Market Access will lead the United States launch of Oncuria."
    Commercial
    |
    Oncuria™